Your browser doesn't support javascript.
loading
Long-term impacts of antibiotic allergy testing on patient perceptions and antibiotic utilization.
Tan, N; Holmes, N E; Chua, K Y; Stewardson, A J; Trubiano, J A.
Afiliación
  • Tan N; Department of Infectious Diseases and Centre for Antibiotic Allergy and Research, Austin Hospital, VIC, Melbourne, Australia.
  • Holmes NE; Department of Infectious Diseases and Centre for Antibiotic Allergy and Research, Austin Hospital, VIC, Melbourne, Australia.
  • Chua KY; Department of Infectious Diseases and Centre for Antibiotic Allergy and Research, Austin Hospital, VIC, Melbourne, Australia.
  • Stewardson AJ; Department of Infectious Diseases, Alfred Health and Central Clinical School, Monash University, VIC, Melbourne, Australia.
  • Trubiano JA; Department of Infectious Diseases and Centre for Antibiotic Allergy and Research, Austin Hospital, VIC, Melbourne, Australia.
JAC Antimicrob Resist ; 1(2): dlz058, 2019 Sep.
Article en En | MEDLINE | ID: mdl-34222932
ABSTRACT

OBJECTIVES:

To define the long-term impacts of antibiotic allergy testing (AAT) on patient allergy perception and antibiotic utilization.

METHODS:

Patients were identified from a prospective AAT database as having completed testing during a 15 month period beginning January 2017. Patients were contacted for a follow-up survey at least 12 months post-AAT. For those contacted, baseline demographics, antibiotic allergy label (AAL) history, age-adjusted Charlson comorbidity index, infection history, antibiotic de-labelling (≥1 AAL removed following AAT) and antibiotic usage for 12 months prior to testing (pre-AAT) and 12 months following testing (post-AAT) were recorded for each patient.

RESULTS:

From the follow-up survey of 112 patients post-AAT, 95.2% (59/62) of patients with complete AAL removal expressed willingness to use 'de-labelled' antibiotics and 91.9% (57/62) were adherent to allergy label modification. Comparing antibiotic utilization 12 months pre-AAT versus 12 months post-AAT, AAT was associated with a significant increase in preferred antibiotic therapy [adjusted odds ratio (aOR) 3.29, 95% CI 1.56-6.92] and reduction in restricted antibiotic utilization (aOR 0.42, 95% CI 0.19-0.93).

CONCLUSIONS:

An antimicrobial stewardship (AMS)-led AAT programme was safe and effective in the long term in the promotion of preferred and narrow-spectrum antibiotic usage, and favourable patient perception towards the AAT testing results was identified. This study further supports the routine incorporation of AAT into AMS programmes, confirming safety and durability of testing impacts on patients as well as increasing preferred antibiotic utilization.

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: JAC Antimicrob Resist Año: 2019 Tipo del documento: Article País de afiliación: Australia

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: JAC Antimicrob Resist Año: 2019 Tipo del documento: Article País de afiliación: Australia